Company / Current Liabilities
Edgewise Therapeutics, Inc. Current Liabilities History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$27.4M
FY2025
5-year range
$10.5M / $27.4M
FY2021-FY2025
Trend
+14.7%
vs FY2024
Sector context
#179 of 213
Health Care
What the data says
Edgewise Therapeutics, Inc.'s current liabilities of $27M is lower than 84% of companies in the Health Care sector (FY2025). Current Liabilities has increased for 5 consecutive years, from $4M in FY2020 to $27M in FY2025.
Based on SEC 10-K filings.
$27M in FY2025 with a 5-year CAGR of +44.5%.
Increased from $17M to $27M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +18.2%
- 5-Year CAGR
- +44.5%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 213This company $27.4M Sector average $1.6B
▼
-98.3% below sector average
Key checks
Key Insights
- Edgewise Therapeutics, Inc.'s current liabilities has grown for 5 consecutive years.
- 5-year CAGR of +44.5%, indicating consistent growth.
- In FY2025, current liabilities increased 14.7% year-over-year.
- Ranks #179 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.4M | +14.7% |
| FY2024 | $23.9M | +42.3% |
| FY2023 | $16.8M | +1.1% |
| FY2022 | $16.6M | +57.6% |
| FY2021 | $10.5M | +142.3% |
| FY2020 | $4.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026